Understanding SCARNA11's Role in Cancer (G677780)

Target Name: SCARNA11

NCBI ID: G677780

SCARNA11

Other Name(s): ACA57 | Small Cajal body-specific RNA 11 | small Cajal body-specific RNA 11

Understanding SCARNA11's Role in Cancer

SCARNA11 (ACA57) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the scaffold protein family, which plays a critical role in the structure and function of tissues.

One of the unique features of SCARNA11 is its ability to interact with several different proteins, including the protein known as TSPO (Tissue-Specific Protein). This interaction between SCARNA11 and TSPO has been shown to play a role in the regulation of pancreatic development and function.

In addition to its role in cell signaling, SCARNA11 has also been shown to be involved in the development and progression of several diseases, including cancer. For example, studies have shown that SCARNA11 is often overexpressed in various types of cancer, and that this overexpression is associated with a number of negative outcomes, including increased cancer cell proliferation and the development of drug resistance.

Despite these promising findings, much more research is needed about the role of SCARNA11 in cancer. In particular, there is a need for better understanding of how SCARNA11 interacts with its various partners in the cell and how this interaction contributes to the development and progression of cancer.

In conclusion, SCARNA11 is a protein that has the potential to be a drug target or biomarker for a variety of diseases, including cancer. Further research is needed to better understand its role in cell signaling and its potential as a therapeutic target.

Protein Name: Small Cajal Body-specific RNA 11

The "SCARNA11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SCARNA11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets